Biochemical characterization of two novel mutations in the human high-affinity choline transporter 1 identified in a patient with congenital myasthenic syndrome
Human Molecular Genetics · 2023
DOI: 10.1093/hmg/ddac309 ↗Kurz gefasst
Fallbericht in der Zeitschrift Human Molecular Genetics, 2023. Verfasst von Midhat Rizvi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Myasthenic Syndromes, Congenital, Mutant Proteins, Symporters, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: CIHR.
Abstract (Originalsprache)
Congenital myasthenic syndrome (CMS) is a heterogeneous condition associated with 34 different genes, including SLC5A7, which encodes the high-affinity choline transporter 1 (CHT1). CHT1 is expressed in presynaptic neurons of the neuromuscular junction where it uses the inward sodium gradient to reuptake choline. Biallelic CHT1 mutations often lead to neonatal lethality, and less commonly to non-lethal motor weakness and developmental delays. Here, we report detailed biochemical characterization of two novel mutations in CHT1, p.I294T and p.D349N, which we identified in an 11-year-old patient with a history of neonatal respiratory distress, and subsequent hypotonia and global developmental delay. Heterologous expression of each CHT1 mutant in human embryonic kidney cells showed two different mechanisms of reduced protein function. The p.I294T CHT1 mutant transporter function was detectable, but its abundance and half-life were significantly reduced. In contrast, the p.D349N CHT1 mutant was abundantly expressed at the cell membrane, but transporter function was absent. The residual function of the p.I294T CHT1 mutant may explain the non-lethal form of CMS in this patient, and the divergent mechanisms of reduced CHT1 function that we identified may guide future functional studies of the CHT1 myasthenic syndrome. Based on these in vitro studies that provided a diagnosis, treatment with cholinesterase inhibitor together with physical and occupational therapy significantly improved the patient’s strength and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Physiology, University of Alberta, Edmonton, Alberta, Canada.
- Membrane Protein Disease Research Group, University of Alberta, Edmonton, Alberta, Canada.
- Center for Human Genetics and Genomics, New York University Grossman School of Medicine, New York, NY, USA.
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
- Clinical Genetics, New York University Langone Orthopedic Hospital, New York, NY, USA.
- Division of Clinical Genetics, Department of Pediatrics, New York University Grossman School of Medicine, New York, NY, USA.
ORCID-Profile: Emmanuelle Cordat
Förderung
- CIHR
Zitieren
APA
Rizvi, M., Truong, T. K., Zhou, J., Batta, M., Moran, E. S., Pappas, J., Chu, M. L., Caluseriu, O., Evrony, G. D., Leslie, E. M., & Cordat, E. (2023). Biochemical characterization of two novel mutations in the human high-affinity choline transporter 1 identified in a patient with congenital myasthenic syndrome. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddac309
Vancouver
Rizvi M, Truong TK, Zhou J, Batta M, Moran ES, Pappas J, et al. Biochemical characterization of two novel mutations in the human high-affinity choline transporter 1 identified in a patient with congenital myasthenic syndrome. Human Molecular Genetics. 2023. doi:10.1093/hmg/ddac309
BibTeX
@article{Rizvi2023,
author = {Rizvi, Midhat and Truong, Tina K and Zhou, Janet and Batta, Manav and Moran, Ellen S and Pappas, John and Chu, Mary Lynn and Caluseriu, Oana and Evrony, Gilad D and Leslie, Elaine M and Cordat, Emmanuelle},
title = {Biochemical characterization of two novel mutations in the human high-affinity choline transporter 1 identified in a patient with congenital myasthenic syndrome},
journal = {Human Molecular Genetics},
year = {2023},
doi = {10.1093/hmg/ddac309}
}
EUVIMED